Table 2.
Multivariable Logistic Regression Model with Significant Clinical Risk Factors and Dose Effect of Top SNPs
| Characteristics | Cases | Controls | OR | 95% Wald CI | P-value | |||
|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | |||||
| Final Clinical Model (n = 591) | ||||||||
| Treatment arm | .0243 | |||||||
| TMZ+placebo | 54 | 40.3 | 239 | 52.3 | 1 | |||
| TMZ+BEV | 80 | 59.7 | 218 | 47.7 | 1.60 | 1.06 | 2.38 | |
| Gender | <.0001 | |||||||
| Male | 52 | 38.8 | 308 | 67.4 | 1 | |||
| Female | 82 | 61.2 | 149 | 32.6 | 2.98 | 2.00 | 4.45 | |
| Anticonvulsants | .0386 | |||||||
| No | 29 | 21.6 | 133 | 29.1 | 1 | |||
| Yes | 105 | 78.4 | 324 | 70.9 | 1.65 | 1.03 | 2.65 | |
| Final Clinical+SNP Model (n = 367) | ||||||||
| Treatment arm | .0441 | |||||||
| TMZ+placebo | 30 | 36.1 | 153 | 53.9 | 1 | |||
| TMZ+BEV | 53 | 63.9 | 131 | 46.1 | 1.82 | 1.02 | 3.27 | |
| Gender | <.0001 | |||||||
| Male | 31 | 37.4 | 194 | 68.3 | 1 | |||
| Female | 52 | 62.7 | 90 | 31.7 | 4.45 | 2.45 | 8.08 | |
| Anticonvulsants | .1442 | |||||||
| No | 20 | 24.1 | 88 | 31.1 | 1 | |||
| Yes | 63 | 75.9 | 196 | 69.0 | 1.64 | 0.85 | 3.18 | |
| Top SNPs dose effect, number at-risk alleles | Median = 6, IQR = 4–7 | Median = 3, IQR = 1–5 | 1.64 | 1.43 | 1.89 | <.0001 | ||
Abbreviations: BEV, bevacizumab; CI, confidence interval; IQR, inter-quartile range; OR, odds ratio; SNP, single nucleotide polymorphism; TMZ, temozolomide.